regulatory
confidence high
sentiment positive
materiality 0.55
Cumberland Pharma receives FDA Orphan Drug and Rare Pediatric Disease designations for Ifetroban in DMD
CUMBERLAND PHARMACEUTICALS INC
- FDA granted Orphan Drug and Rare Pediatric Disease Designations to Ifetroban for cardiomyopathy associated with Duchenne muscular dystrophy.
- Cumberland is completing the FIGHT DMD Phase II trial; results expected later in 2024.
- Rare Pediatric Disease Designation may qualify company for a priority review voucher upon approval.
- Orphan Drug Designation provides seven-year market exclusivity, tax credits, and fee waivers if approved.